A Comparison of Bone Marrow Morphology and Peripheral Blood Findings in Low and High Level JAK2 V617F Allele Burden
Abstract
:1. Introduction
2. Materials and Methods
2.1. Bone Marrow Biopsy Evaluation
2.2. DNA Isolation and JAK2 V617F Mutation Analysis
2.3. Statistical Analysis
3. Results
3.1. Diagnoses within Low and High JAK2 V617F Allele Burden Groups
3.2. Comparison of the Bone Marrow Morphology and Peripheral Blood Findings in the Low Level and High Level JAK2 V617F Allele Burden Groups
3.3. Comparison of the Bone Marrow Morphology and Peripheral Blood Findings within the Low Level JAK2 V617F Allele Burden Group
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- James, C.; Ugo, V.; Le Couedic, J.P.; Staerk, J.; Delhommeau, F.; Lacout, C.; Garcon, L.; Raslova, H.; Berger, R.; Bennaceur-Griscelli, A.; et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434, 1144–1148. [Google Scholar] [CrossRef]
- Nangalia, J.; Massie, C.E.; Baxter, E.J.; Nice, F.L.; Gundem, G.; Wedge, D.C.; Avezov, E.; Li, J.; Kollmann, K.; Kent, D.G.; et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Engl. J. Med. 2013, 369, 2391–2405. [Google Scholar] [CrossRef] [Green Version]
- Tefferi, A.; Noel, P.; Hanson, C.A. Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology. J. Mol. Diagn. 2011, 13, 461–466. [Google Scholar] [CrossRef]
- Malak, S.; Labopin, M.; Saint-Martin, C.; Bellanne-Chantelot, C.; Najman, A.; French Group of Familial Myeloproliferative Disorders. Long term follow up of 93 families with myeloproliferative neoplasms: Life expectancy and implications of JAK2V617F in the occurrence of complications. Blood Cells Mol. Dis. 2012, 49, 170–176. [Google Scholar] [CrossRef] [PubMed]
- Tefferi, A.; Lasho, T.L.; Huang, J.; Finke, C.; Mesa, R.A.; Li, C.Y.; Wu, W.; Hanson, C.A.; Pardanani, A. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008, 22, 756–761. [Google Scholar] [CrossRef] [PubMed]
- Guglielmelli, P.; Barosi, G.; Specchia, G.; Rambaldi, A.; Lo Coco, F.; Antonioli, E.; Pieri, L.; Pancrazzi, A.; Ponziani, V.; Delaini, F.; et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009, 114, 1477–1483. [Google Scholar] [CrossRef] [Green Version]
- Perricone, M.; Polverelli, N.; Martinelli, G.; Catani, L.; Ottaviani, E.; Zuffa, E.; Franchini, E.; Dizdari, A.; Forte, D.; Sabattini, E.; et al. The relevance of a low JAK2V617F allele burden in clinical practice: A monocentric study. Oncotarget 2017, 8, 37239–37249. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Waterhouse, M.; Follo, M.; Pfeifer, D.; von Bubnoff, N.; Duyster, J.; Bertz, H.; Finke, J. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR. Ann. Hematol. 2016, 95, 739–744. [Google Scholar] [CrossRef]
- Lippert, E.; Mansier, O.; Migeon, M.; Denys, B.; Nilsson, A.; Rosmond, C.; Lode, L.; Ugo, V.; Lascaux, A.; Bellosillo, B.; et al. Clinical and biological characterization of patients with low (0.1–2%) JAK2V617F allele burden at diagnosis. Haematologica 2014, 99, e98–e101. [Google Scholar] [CrossRef] [Green Version]
- Martinaud, C.; Brisou, P.; Mozziconacci, M.J. Is the JAK2(V617F) mutation detectable in healthy volunteers? Am. J. Hematol. 2010, 85, 287–288. [Google Scholar] [CrossRef]
- Sidon, P.; El Housni, H.; Dessars, B.; Heimann, P. The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia 2006, 20, 1622. [Google Scholar] [CrossRef] [PubMed]
- Vannucchi, A.M.; Pieri, L.; Guglielmelli, P. JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. Ther. Adv. Hematol. 2011, 2, 21–32. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Larsen, T.S.; Pallisgaard, N.; Moller, M.B.; Hasselbalch, H.C. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype. Eur. J. Haematol. 2007, 79, 508–515. [Google Scholar] [CrossRef] [PubMed]
- Vannucchi, A.M.; Antonioli, E.; Guglielmelli, P.; Pardanani, A.; Tefferi, A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: A critical reappraisal. Leukemia 2008, 22, 1299–1307. [Google Scholar] [CrossRef]
- Vannucchi, A.M.; Antonioli, E.; Guglielmelli, P.; Rambaldi, A.; Barosi, G.; Marchioli, R.; Marfisi, R.M.; Finazzi, G.; Guerini, V.; Fabris, F.; et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007, 110, 840–846. [Google Scholar] [CrossRef]
- Koren-Michowitz, M.; Landman, J.; Cohen, Y.; Rahimi-Levene, N.; Salomon, O.; Michael, M.; Amariglio, N.; Nagler, A. JAK2V617F allele burden is associated with transformation to myelofibrosis. Leuk. Lymphoma 2012, 53, 2210–2213. [Google Scholar] [CrossRef]
- How, J.; Trinkaus, K.M.; Oh, S.T. Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic vein thrombosis. Br. J. Haematol. 2018, 183, 310–313. [Google Scholar] [CrossRef] [Green Version]
- Borowczyk, M.; Wojtaszewska, M.; Lewandowski, K.; Gil, L.; Lewandowska, M.; Lehmann-Kopydlowska, A.; Kroll-Balcerzak, R.; Balcerzak, A.; Iwola, M.; Michalak, M.; et al. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. Thromb. Res. 2015, 135, 272–280. [Google Scholar] [CrossRef]
- Jaiswal, S.; Natarajan, P.; Silver, A.J.; Gibson, C.J.; Bick, A.G.; Shvartz, E.; McConkey, M.; Gupta, N.; Gabriel, S.; Ardissino, D.; et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N. Engl. J. Med. 2017, 377, 111–121. [Google Scholar] [CrossRef]
- Wu, X.; Lee, J.W.; Peker, D.; Spitzer, S.G.; Laser, J.; Reddy, V.V.; Harada, S. Is Low Positive JAK2 V617F Mutation Test Result Clinically Significant? Multi-Institutional Study. Appl. Immunohistochem. Mol. Morphol. 2016, 24, 589–594. [Google Scholar] [CrossRef]
- Nussenzveig, R.H.; Pham, H.T.; Perkins, S.L.; Prchal, J.T.; Agarwal, A.M.; Salama, M.E. Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2(V617F) allelic burden. Leuk. Lymphoma. 2016, 57, 1429–1435. [Google Scholar] [CrossRef] [PubMed]
- Thiele, J.; Kvasnicka, H.M.; Facchetti, F.; Franco, V.; van der Walt, J.; Orazi, A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005, 90, 1128–1132. [Google Scholar] [PubMed]
- Swerdlow, S.H.; Campo, E.; Harris, N.L.; Jaffe, E.S.; Pileri, S.A.; Stein, H.; Thiele, J.; Vardiman, J.W. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues; International Agency for Research on Cancer Lyon: Lyon, France, 2008; Volume 2. [Google Scholar]
- Swerdlow, S.H.; Campo, E.; Pileri, S.A.; Harris, N.L.; Stein, H.; Siebert, R.; Advani, R.; Ghielmini, M.; Salles, G.A.; Zelenetz, A.D.; et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016, 127, 2375–2390. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Koopmans, S.M.; Bot, F.J.; Lam, K.H.; van Marion, A.M.; de Raeve, H.; Hebeda, K.M. Reproducibility of histologic classification in nonfibrotic myeloproliferative neoplasia. Am. J. Clin. Pathol. 2011, 136, 618–624. [Google Scholar] [CrossRef] [Green Version]
- Nielsen, C.; Bojesen, S.E.; Nordestgaard, B.G.; Kofoed, K.F.; Birgens, H.S. JAK2V617F somatic mutation in the general population: Myeloproliferative neoplasm development and progression rate. Haematologica 2014, 99, 1448–1455. [Google Scholar] [CrossRef]
- Levraut, M.; Legros, L.; Drappier, C.; Bene, M.C.; Queyrel, V.; Raynaud, S.; Martis, N. Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: A retrospective impact study. J. Thromb. Thrombolysis 2020, 50, 995–1003. [Google Scholar] [CrossRef]
- Mooney, L.; Goodyear, C.S.; Chandra, T.; Kirschner, K.; Copland, M.; Petrie, M.C.; Lang, N.N. Clonal haematopoiesis of indeterminate potential: Intersections between inflammation, vascular disease and heart failure. Clin. Sci. 2021, 135, 991–1007. [Google Scholar] [CrossRef]
- Steensma, D.P. Clinical consequences of clonal hematopoiesis of indeterminate potential. Hematol. Am. Soc. Hematol. Educ. Program 2018, 2018, 264–269. [Google Scholar] [CrossRef] [Green Version]
- Jaiswal, S.; Fontanillas, P.; Flannick, J.; Manning, A.; Grauman, P.V.; Mar, B.G.; Lindsley, R.C.; Mermel, C.H.; Burtt, N.; Chavez, A.; et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 2014, 371, 2488–2498. [Google Scholar] [CrossRef] [Green Version]
- Delluc, A.; Antic, D.; Lecumberri, R.; Ay, C.; Meyer, G.; Carrier, M. Occult cancer screening in patients with venous thromboembolism: Guidance from the SSC of the ISTH. J. Thromb. Haemost. 2017, 15, 2076–2079. [Google Scholar] [CrossRef] [Green Version]
- Bader, M.S.; Meyer, S.C. JAK2 in myeloproliferative neoplasms: Still a protagonist. Pharmaceuticals 2022, 15, 160. [Google Scholar] [CrossRef] [PubMed]
Demographics | Low JAK2 V617F | High JAK2 V617F | |
---|---|---|---|
<3% (n = 15) | ≥3% but ≤15% (n = 47) | >15% (n = 60) | |
Mean age, years (range) | 57 (28–91) | 61 (23–86) | 69 (39–91) |
Subjects aged ≤60 years, n (%) | 9 (60) | 19 (40.4) | 13 (21.7) |
Subjects aged >60 years, n (%) | 6 (40) | 28 (59.6) | 47 (78.3) |
Male, n (%) | 8 (53) | 16 (34) | 23 (38) |
Female, n (%) | 7 (47) | 31 (66) | 37 (62) |
Splenomegaly, n (%) | 1 (6.7) | 9 (19.1) | 18 (30) |
Hepatomegaly, n (%) | 1 (6.7) | 2 (4.3) | 2 (3.3) |
Hepatosplenomegaly, n (%) | 1 (6.7) | 2 (4.3) | 6 (10) |
Thrombotic events *, n (%) | 2 (40) | 10 (21.3) | 12 (20) |
JAK2 V617F allele burden, median (range) % | 0.41 (0.019–2.04) | 9 (3.10–15) | 37.75 (15.55–94) |
Characteristic | JAK2 V617F Allel Burden, Median (Range) % | PV | ET | PMF | Unclassified MPN | CHIP | Other | Total |
---|---|---|---|---|---|---|---|---|
<3% | 3 | 4 | 0 | 3 | 1 | 4 | 15 | |
≥3% | 12 | 28 | 3 | 4 | 0 | 0 | 47 | |
Low ≤ 15% n (%) | 7.18 (0.019–15) | 15 (24.2) | 32 (51.6) | 3 (4.8) | 7 (11.3) | 1 (1.6) | 4 (6.5) * | 62 |
High > 15% n (%) | 37.75 (15.55–94) | 31 (51.7) | 12 (20) | 11 (18.3) | 5 (8.3) | 0 | 1 (1.7) & | 60 |
Low ≤15% and High >15% JAK2 V617F Positive n = 122 | |||
---|---|---|---|
Characteristic | ≤15% n = 62 | >15% n = 60 | p Value |
Age (years) n (%) ≤60 >60 | 28 (45.2) 34 (54.8) | 13 (21.7) 47 (78.3) | 0.007 * |
Myelofibrosis 0 1 2 3 | 46 (74.2) 12 (19.4) 4 (6.5) 0 (0) | 31 (51.7) 15 (25) 11 (18.3) 3 (2.5) | 0.023 * |
Cellularity Decreased Normal Increased | 0 (0) 29 (46.8) 33 (53.2) | 1 (1.7) 12 (20) 47 (78.3) | 0.005 * |
Adipocytes Normal Decreased | 30 (48.4) 32 (51.6) | 43 (72.9) 16 (27.1) | 0.009 * |
Erythroid cells ratio Decreased Normal Increased | 9 (14.5) 15 (24.2) 38 (61.3) | 10 (17.2) 6(10.3) 42 (72.4) | 0.137 * |
Myeloid cells ratio Decreased Normal Increased | 10 (16.1) 30 (48.4) 22 (35.5) | 7 (11.9) 12 (20.3) 40 (67.8) | 0.0012 * |
E:M ratio E > M E = M E < M | 22 (35.5) 21 (33.9) 19 (30.6) | 19 (32.8) 18 (31) 21 (36.2) | 0.812 * |
Number of megakaryocytes Decreased Normal Increased | 1 (1.6) 9 (14.5) 52 (83.9) | 0 (0) 4 (6.7) 56 (93.3) | 0.219 * |
Megakaryocytes clustering Yes No | 43 (69.4) 19 (30.6) | 51 (85) 9 (15) | 0.053 * |
Megakryocyte nucleus morphology Normal Hypolobulated Staghorn Maturation defect | 9 (14.5) 8 (12.9) 32 (51.6) 13 (21) | 0 (0) 1 (1.7) 23 (39.0) 35 (59.3) | <0.0001 * |
Megakryocyte atypia Yes No | 53 (85.5) 9 (14.5) | 58 (96.7) 2 (3.3) | 0.054 * |
RBC, median (range) ×1012/L | 5.10 (1.19–6.67) | 5.51 (2.40–8.57) | 0.0057 & |
Hemoglobin, median (range) g/L | 147 (70–191) | 153 (57–229) | 0.1607 & |
Hematocrit, median (range) % | 0.455 (0.206–0.586) | 0.482 (0.23–0.74) | 0.048 & |
WBC, median (range) ×109/L | 9.3 (4.8–20.6) | 10.15 (4.1–34.8) | 0.070 & |
PLT, median (range) ×109/L | 557 (34–1131) | 513 (117–1604) | 0.993 & |
Subject | %JAK2 V617F | Bone Marrow Histology | RBC | WBC | PLT | Final Diagnosis |
---|---|---|---|---|---|---|
S1 | 2.04 | Normal | N | C | N | CHIP/old |
S2 | 0.12 | Suggestive of MPN | Slightly increased | N | N | Probable MPN (PV?) |
S3 | 0.41 | Suggestive of MPN | Slightly increased | N | N | Probable MPN (PV?) |
S4 | 0.23 | MPN | N | N | N | Unclassified MPN |
S5 | 0.54 | Normal | N | N | Slightly increased | Probable ET |
S6 | 0.41 | MPN | N | N | Increased | ET |
S7 | 1.07 | MPN | N | N | Increased | ET |
S8 | 1.49 | MPN | Slightly increased | N | N | Probable MPN (PV?) |
S9 | 0.27 | Normal | N | N | Slightly increased | Probable ET |
S10 | 0.56 | Normal | N | N | N | Not MPN |
S11 | 0.019 | Normal | No data | No data | No data | Not MPN |
S12 | 0.25 | CML | N | Increased | Decreased | CML |
S13 | 1.20 | Suggestive of MPN | Slightly increased | N | N | Probable MPN |
S14 | 0.11 | Suggestive of MPN | Slightly increased | N | N | Probable MPN |
S15 | 0.12 | Normal | Slightly increased | N | N | Not MPN |
Low JAK2 V617F Positive ≤15% n = 62 | |||
---|---|---|---|
Characteristic | <3% n = 15 | ≥3% and ≤15% n = 47 | p Value |
Age (years) n (%) ≤60 >60 | 9 (60) 6 (40) | 19 (40.4) 28 (59.6) | 0.238 * |
Myelofibrosis 0 1 2 | 11 (73.3) 3 (20) 1 (6.7) | 35 (74.5) 9 (19.1) 3 (6.4) | 0.996 * |
Cellularity Normal Increased | 10 (66.7) 5 (33.3) | 19 (40.4) 28 (59.6) | 0.136 * |
Adipocytes Normal Decreased | 10 (66.7) 5 (33.3) | 22 (46.8) 25 (53.2) | 0.239 * |
Erythroid cells ratio Decreased Normal Increased | 2 (13.3) 3 (20) 10 (66.7) | 7 (14.9) 12(25.5) 28 (59.6) | 0.879 * |
Myeloid cells ratio Decreased Normal Increased | 3 (20) 8 (53.3) 4 (26.7) | 7 (14.9) 22 (46.8) 18 (38.3) | 0.699 * |
E:M ratio E > M E = M E < M | 7 (46.7) 4 (26.7) 4 (26.7) | 15 (31.9) 17 (36.2) 15 (31.9) | 0.576 * |
Number of megakaryocytes Decreased Normal Increased | 1 (6.7) 5 (33.3) 9 (60) | 0 (0) 4 (8.5) 43 (91.5) | 0.009 * |
Megakaryocytes clustering Yes No | 5 (33.3) 10 (66.7) | 38 (80.9) 9 (19.1) | 0.001 * |
Megakryocyte nucleus morphology Normal Hypolobulated Staghorn Maturation defect | 7 (46.7) 2 (13.3) 3 (20) 3 (20) | 2 (4.3) 6 (12.8) 29 (61.7) 10 (21.3) | 0.0005 * |
Megakryocyte atypia Yes No | 8 (53.3) 7 (46.7) | 45 (95.7) 2 (4.3) | 0.0003 * |
RBC, median (range) ×1012/L | 5.19 (4.12–6.67) | 5.02 (1.91–6.06) | 0.345 & |
Hemoglobin, median (range) g/L | 152.5 (113–191) | 145 (70–175) | 0.058 & |
Hematocrit, median (range) % | 0.48 (0.35–0.58) | 0.45 (0.20–0.53) | 0.032 & |
WBC, median (range) ×109/L | 9.65 (6.4–20.6) | 9.1 (4.8–15.3) | 0.643 & |
PLT, median (range) ×109/L | 265 (34–1008) | 602 (157–1131) | 0.0003 & |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Babarović, E.; Marijić, B.; Vranić, L.; Ban, J.; Valković, T.; Hadžisejdić, I. A Comparison of Bone Marrow Morphology and Peripheral Blood Findings in Low and High Level JAK2 V617F Allele Burden. Diagnostics 2023, 13, 2086. https://doi.org/10.3390/diagnostics13122086
Babarović E, Marijić B, Vranić L, Ban J, Valković T, Hadžisejdić I. A Comparison of Bone Marrow Morphology and Peripheral Blood Findings in Low and High Level JAK2 V617F Allele Burden. Diagnostics. 2023; 13(12):2086. https://doi.org/10.3390/diagnostics13122086
Chicago/Turabian StyleBabarović, Emina, Blažen Marijić, Luka Vranić, Josipa Ban, Toni Valković, and Ita Hadžisejdić. 2023. "A Comparison of Bone Marrow Morphology and Peripheral Blood Findings in Low and High Level JAK2 V617F Allele Burden" Diagnostics 13, no. 12: 2086. https://doi.org/10.3390/diagnostics13122086